Composite biochemical response favored #saroglitazar over placebo in US and non-US patients with primary biliary cholangitis. #ACG2026

https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/

Zydus Therapeutics Unveils Insights from Phase 3 EPICS-III Trial at ACG 2026 #India #Ahmedabad #Saroglitazar #PBC #Zydus_Therapeutics